Background: Vitamin D repletion is recommended for secondary hyperparathyroidism (SHPT)
and associated vitamin D insufficiency (VDI) in chronic kidney disease (CKD), but optimal …

Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia in patients
with CKD, including those receiving dialysis, although clinical trials have identified risks …

Background Morbidity and mortality vary seasonally. Timing and severity of influenza seasons
contribute to those patterns, especially among vulnerable populations such as patients …

Objectives This double-blind randomized controlled trial investigated raising serum 25-hydroxyvitamin
D (25D) with extended-release calcifediol (ERC) on time to symptom resolution in …

Background Real-world incidence, clinical consequences, and healthcare resource utilization
(HRU) of hyperkalemia (HK) remain poorly characterized, particularly in patients with …

Introduction: Parathyroid hormone-lowering responses after administration of three different
therapies capable of raising serum total 25-hydroxyvitamin D (25OHD) were evaluated in …

Introduction: Obesity increases the risk of vitamin D insufficiency, which exacerbates secondary
hyperparathyroidism in chronic kidney disease. Recent studies suggest that serum total …

Clinical guidelines recommend concurrent treatment of anemia in end‐stage renal disease
with erythropoiesis‐stimulating agents ( ESA s) and iron. However, there are mixed data …

Introduction: The safety and efficacy of extended-release calcifediol (ERC) as a treatment for
secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (…

Little is known about the most important factors that inform a nephrologist’s decision to treat (DTT)
pre-dialysis chronic kidney disease (CKD) patients with vitamin D insufficiency (VDI) …